{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:18:26Z","timestamp":1793744306045,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"the Mayo Translational Polycystic Kidney Disease Center","award":["NIDDK P30 DK090728"],"award-info":[{"award-number":["NIDDK P30 DK090728"]}]},{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"crossref","award":["Kolff PhD Fellowship Abroad Grant"],"award-info":[{"award-number":["Kolff PhD Fellowship Abroad Grant"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12882-017-0578-6","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T12:32:34Z","timestamp":1495715554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression"],"prefix":"10.1186","volume":"18","author":[{"given":"Myrte K.","family":"Neijenhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wietske","family":"Kievit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff A.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Erwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hassan","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom J. G.","family":"Gevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P. H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"issue":"4","key":"578_CR1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2004.12.021","volume":"45","author":"RL Perlman","year":"2005","unstructured":"Perlman RL, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005;45(4):658\u201366.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"578_CR2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/ajkd.2002.31401","volume":"39","author":"JW Kusek","year":"2002","unstructured":"Kusek JW, et al. Cross-sectional study of health-related quality of life in African Americans with chronic renal insufficiency: the African American Study of Kidney Disease and Hypertension Trial. Am J Kidney Dis. 2002;39(3):513\u201324.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"578_CR3","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1053\/ajkd.2003.50121","volume":"41","author":"FY Chow","year":"2003","unstructured":"Chow FY, et al. Health-related quality of life in Australian adults with renal insufficiency: a population-based study. Am J Kidney Dis. 2003;41(3):596\u2013604.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"578_CR4","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1172\/JCI114280","volume":"84","author":"KU Eckardt","year":"1989","unstructured":"Eckardt KU, et al. Erythropoietin in polycystic kidneys. J Clin Invest. 1989;84(4):1160\u20136.","journal-title":"J Clin Invest"},{"issue":"1","key":"578_CR5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000183332","volume":"39","author":"M Chandra","year":"1985","unstructured":"Chandra M, et al. Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron. 1985;39(1):26\u20139.","journal-title":"Nephron"},{"issue":"Suppl 4","key":"578_CR6","doi-asserted-by":"crossref","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","volume":"29","author":"EM Spithoven","year":"2014","unstructured":"Spithoven EM, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2014;29(Suppl 4):iv15\u201325.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"578_CR7","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1053\/j.ajkd.2013.07.004","volume":"62","author":"RD Perrone","year":"2013","unstructured":"Perrone RD, et al. Patient-Reported Outcomes in Clinical Trials of CKD-Related Therapies: Report of a Symposium Sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2013;62(6):1046\u201357.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"578_CR8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.00080605","volume":"1","author":"KT Bae","year":"2006","unstructured":"Bae KT, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006;1(1):64\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"14","key":"578_CR9","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477\u201385.","journal-title":"N Engl J Med"},{"issue":"9569","key":"578_CR10","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287\u2013301.","journal-title":"Lancet"},{"issue":"1","key":"578_CR11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","volume":"1","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006;1(1):148\u201357.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"578_CR12","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.12430","volume":"34","author":"TF Wijnands","year":"2014","unstructured":"Wijnands TF, et al. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int. 2014;34(10):1578\u201383.","journal-title":"Liver Int"},{"issue":"2","key":"578_CR13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1053\/j.ajkd.2013.08.017","volume":"63","author":"DC Miskulin","year":"2014","unstructured":"Miskulin DC, et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis. 2014;63(2):214\u201326.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"578_CR14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cgh.2014.07.051","volume":"13","author":"MC Hogan","year":"2015","unstructured":"Hogan MC, et al. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015;13(1):155\u201364. e6","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"578_CR15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1471-2369-14-179","volume":"14","author":"T Suwabe","year":"2013","unstructured":"Suwabe T, et al. Quality of life of patients with ADPKD - Toranomon PKD QOL study: Cross-sectional study. BMC Nephrol. 2013;14(1):179.","journal-title":"BMC Nephrol"},{"issue":"3","key":"578_CR16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2215\/CJN.02410508","volume":"4","author":"D Rizk","year":"2009","unstructured":"Rizk D, et al. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol. 2009;4(3):560\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"578_CR17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1\u201334.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"578_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","volume":"20","author":"Y Pei","year":"2009","unstructured":"Pei Y, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205\u201312.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"578_CR19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.5535\/arm.2014.38.5.665","volume":"38","author":"J Kim","year":"2014","unstructured":"Kim J, et al. Correlations between electrically quantified pain degree, subjectively assessed visual analogue scale, and the McGill pain questionnaire: a pilot study. Ann Rehabil Med. 2014;38(5):665\u201372.","journal-title":"Ann Rehabil Med"},{"issue":"5","key":"578_CR20","first-page":"360","volume":"37","author":"AJ Viera","year":"2005","unstructured":"Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360\u20133.","journal-title":"Fam Med"},{"key":"578_CR21","unstructured":"Wells GA, S.B., O'Connell D, Petersen J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm ]."},{"issue":"11","key":"578_CR22","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","volume":"21","author":"SG Thompson","year":"2002","unstructured":"Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559\u201373.","journal-title":"Stat Med"},{"key":"578_CR23","doi-asserted-by":"crossref","first-page":"a3006","DOI":"10.1136\/bmj.a3006","volume":"338","author":"DG Contopoulos-Ioannidis","year":"2009","unstructured":"Contopoulos-Ioannidis DG, et al. Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review. BMJ. 2009;338:a3006.","journal-title":"BMJ"},{"issue":"5","key":"578_CR24","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1046\/j.1523-1755.2003.00289.x","volume":"64","author":"S Fukuhara","year":"2003","unstructured":"Fukuhara S, et al. Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2003;64(5):1903\u201310.","journal-title":"Kidney Int"},{"issue":"4 Suppl","key":"578_CR25","first-page":"AS264","volume":"33","author":"JE Ware Jr","year":"1995","unstructured":"Ware JE Jr, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33(4 Suppl):AS264\u201379.","journal-title":"Med Care"},{"issue":"11","key":"578_CR26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0895-4356(98)00108-5","volume":"51","author":"JE Ware Jr","year":"1998","unstructured":"Ware JE Jr, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51(11):1167\u201370.","journal-title":"J Clin Epidemiol"},{"key":"578_CR27","volume-title":"SF-36 physical and mental health summary scales: a users's manual","author":"JE Ware","year":"1994","unstructured":"Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a users's manual. Boston: Health institute, New England Medical Center; 1994."},{"issue":"2","key":"578_CR28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1023\/B:QURE.0000018472.46236.05","volume":"13","author":"J Alonso","year":"2004","unstructured":"Alonso J, et al. Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res. 2004;13(2):283\u201398.","journal-title":"Qual Life Res"},{"issue":"1","key":"578_CR29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","volume":"80","author":"AS Levey","year":"2011","unstructured":"Levey AS, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17\u201328.","journal-title":"Kidney Int"},{"issue":"9","key":"578_CR30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"3","key":"578_CR31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"12","key":"578_CR32","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol. 2011;64(12):1294\u2013302.","journal-title":"J Clin Epidemiol"},{"key":"578_CR33","doi-asserted-by":"crossref","unstructured":"Wallace, B.C., Issa J. Dahabreh, Thomas A. Trikalinos, Joseph Lau, Paul Trow, and Christopher H. Schmid, Closing the Gap between Methodologists and End-Users: R as a Computational Back-End. J Stat Softw. 2012;49(5):1\u201315.","DOI":"10.18637\/jss.v049.i05"},{"issue":"2","key":"578_CR34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1590\/S0101-28002011000200002","volume":"33","author":"BP Barros de","year":"2011","unstructured":"de Barros BP, et al. Anxiety, depression, and quality of life in patients with familial glomerulonephritis or autosomal dominant polycystic kidney disease. J Bras Nefrol. 2011;33(2):120\u20138.","journal-title":"J Bras Nefrol"},{"issue":"6","key":"578_CR35","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","volume":"21","author":"MC Hogan","year":"2010","unstructured":"Hogan MC, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol. 2010;21(6):1052\u201361.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"578_CR36","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","volume":"137","author":"L Keimpema van","year":"2009","unstructured":"van Keimpema L, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009;137(5):1661\u20138. e1-2","journal-title":"Gastroenterology"},{"issue":"6","key":"578_CR37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/089277903767923100","volume":"17","author":"DI Lee","year":"2003","unstructured":"Lee DI, et al. Laparoscopic cyst decortication in autosomal dominant polycystic kidney disease: Impact on pain, hypertension, and renal function. J Endourol. 2003;17(6):345\u201354.","journal-title":"J Endourol"},{"issue":"7","key":"578_CR38","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ndt\/gfv299","volume":"31","author":"RJ Simms","year":"2016","unstructured":"Simms RJ, et al. Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2016;31(7):1130\u201340.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"578_CR39","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jhep.2014.06.024","volume":"61","author":"F Temmerman","year":"2014","unstructured":"Temmerman F, et al. Development and validation of a polycystic liver disease complaint-specific assessment (POLCA). J Hepatol. 2014;61(5):1143\u201350.","journal-title":"J Hepatol"},{"issue":"1","key":"578_CR40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","volume":"59","author":"M Chrispijn","year":"2013","unstructured":"Chrispijn M, et al. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial. J Hepatol. 2013;59(1):153\u20139.","journal-title":"J Hepatol"},{"issue":"5","key":"578_CR41","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/liv.12726","volume":"35","author":"TJ Gevers","year":"2015","unstructured":"Gevers TJ, et al. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver Int. 2015;35(5):1607\u201314.","journal-title":"Liver Int"},{"issue":"5","key":"578_CR42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ckj\/sfv060","volume":"8","author":"A Baker","year":"2015","unstructured":"Baker A, et al. Understanding the physical and emotional impact of early-stage ADPKD: experiences and perspectives of patients and physicians. Clin Kidney J. 2015;8(5):531\u20137.","journal-title":"Clin Kidney J"},{"issue":"5","key":"578_CR43","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ndt\/gfv010","volume":"30","author":"A Tong","year":"2015","unstructured":"Tong A, et al. A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research. Nephrol Dial Transplant. 2015;30(5):790\u2013800.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"578_CR44","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102\u20139.","journal-title":"J Clin Epidemiol"},{"key":"578_CR45","unstructured":"D. Oberdhan, A.B.C., R. D. Perrone, A. L. Serra, J. C. Cole, W. Zhou, H. Krasa, J. Blais, F. S. Czerwiec, Patient Reported Health Related Quality of Life in ADPKD: Analysis from OVERTURE. American Society of Nephrology - Kidney Week 2015, San Diego, US, SA-PO871, 2015."},{"issue":"5","key":"578_CR46","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/apt.13301","volume":"42","author":"MK Neijenhuis","year":"2015","unstructured":"Neijenhuis MK, et al. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials. Aliment Pharmacol Ther. 2015;42(5):591\u20138.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-017-0578-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T01:55:09Z","timestamp":1569376509000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-017-0578-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["578"],"URL":"https:\/\/doi.org\/10.1186\/s12882-017-0578-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]},"article-number":"169"}}